1. Home
  2. AGIO vs NATL Comparison

AGIO vs NATL Comparison

Compare AGIO & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • NATL
  • Stock Information
  • Founded
  • AGIO 2007
  • NATL 2023
  • Country
  • AGIO United States
  • NATL United States
  • Employees
  • AGIO N/A
  • NATL N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • NATL
  • Sector
  • AGIO Health Care
  • NATL
  • Exchange
  • AGIO Nasdaq
  • NATL Nasdaq
  • Market Cap
  • AGIO 2.0B
  • NATL 1.8B
  • IPO Year
  • AGIO 2013
  • NATL N/A
  • Fundamental
  • Price
  • AGIO $30.28
  • NATL $26.62
  • Analyst Decision
  • AGIO Buy
  • NATL Buy
  • Analyst Count
  • AGIO 8
  • NATL 3
  • Target Price
  • AGIO $56.57
  • NATL $40.00
  • AVG Volume (30 Days)
  • AGIO 637.9K
  • NATL 538.5K
  • Earning Date
  • AGIO 05-01-2025
  • NATL 03-03-2025
  • Dividend Yield
  • AGIO N/A
  • NATL N/A
  • EPS Growth
  • AGIO N/A
  • NATL N/A
  • EPS
  • AGIO 11.64
  • NATL 1.23
  • Revenue
  • AGIO $36,498,000.00
  • NATL $4,317,000,000.00
  • Revenue This Year
  • AGIO $50.61
  • NATL $3.85
  • Revenue Next Year
  • AGIO $223.79
  • NATL $3.95
  • P/E Ratio
  • AGIO $2.60
  • NATL $21.62
  • Revenue Growth
  • AGIO 36.07
  • NATL 3.01
  • 52 Week Low
  • AGIO $27.14
  • NATL $19.00
  • 52 Week High
  • AGIO $62.58
  • NATL $35.50
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 39.54
  • NATL 41.51
  • Support Level
  • AGIO $30.00
  • NATL $27.06
  • Resistance Level
  • AGIO $32.90
  • NATL $28.12
  • Average True Range (ATR)
  • AGIO 1.22
  • NATL 0.90
  • MACD
  • AGIO -0.08
  • NATL 0.24
  • Stochastic Oscillator
  • AGIO 9.12
  • NATL 55.31

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

Share on Social Networks: